Interested in specific Information?

Filter what you see here

Relapsed/refractory patients

Quick poll

Results from the OPTIMISMM phase III trial: Pomalidomide for…

Results from the OPTIMISMM phase III trial: Pomalidomide for lenalidomide-refractory patients

Closes May 24, 2019

General MM

Quick poll

COMy 2019 | DEBATE: Are we ready to personalize therapy in multiple…

Closes May 23, 2019

Relapsed/refractory patients

Quick poll

COMy 2019 | DEBATE: CAR T-cell therapy in first relapse

Closes May 22, 2019

Patients non-eligible for transplant

Quick poll

European commission approves lenalidomide and pomalidomide triplets for…

European commission approves lenalidomide and pomalidomide triplets for multiple myeloma

Closes May 21, 2019

General MM

Quick poll

NICE approves lenalidomide in front-line multiple myeloma treatment 

Closes May 21, 2019

Patients eligible for transplant

Quick poll

Autologous stem cell transplantation in multiple myeloma: the big questions

Closes May 15, 2019 , Expert Opinions

Patients eligible for transplant

Quick poll

Autologous stem cell transplant in multiple myeloma: optimal regimens

Autologous stem cell transplant in multiple myeloma: optimal regimens

Closes May 15, 2019 , Expert Opinion

Patients eligible for transplant

Quick poll

Allogeneic stem cell transplantation in multiple myeloma 

Closes May 14, 2019

Relapsed/refractory patients

Quick poll

P-BCMA-101 granted orphan drug designation in relapsed/refractory multiple…

Closes May 14, 2019

Relapsed/refractory patients

Quick poll

CLR 131 receives FDA fast track designation in relapsed/refractory…

CLR 131 receives FDA fast track designation in relapsed/refractory multiple myeloma

Closes May 14, 2019

Relapsed/refractory patients

Quick poll

Phase I results for anti-BCMA CAR T-cell therapy bb2121 

Closes May 10, 2019

Patients eligible for transplant,   General MM

Quick poll

Phase II Carthadex study: carfilzomib, thalidomide and dexamethasone for…

Closes May 9, 2019

Patients eligible for transplant

Quick poll

EBMT 2019 | The role of renal impairment in patients with multiple myeloma…

EBMT 2019 | The role of renal impairment in patients with multiple myeloma undergoing autologous stem cell transplantation

Closes May 2, 2019

General MM

Quick poll

Allogeneic versus patient-derived CAR T therapies in multiple…

Closes Apr 29, 2019 , Expert Opinion

General MM

Quick poll

ESH 2019 | Bone disease in multiple myeloma: continuous versus…

Closes Apr 26, 2019
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Latest Congress Coverage

Relapsed/refractory patients

COMy 2019 | DEBATE: CAR T-cell therapy in first relapse

May 22, 2019

Latest Biology

English & Dutch
Patients non-eligible for transplant,

Sonja Zweegman | ESH MM 2019 | The impact of age on clinical decision-making

Apr 7, 2019

Latest Drug Updates

Recently updated Licenses

Where we are next

American Society of Clinical Oncology (ASCO) 2019 Meeting

May 31 - June 4, 2019 | Chicago, Illinois, US

The Multiple Myeloma Hub will be attending the 2019 Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, US. We will be presenting live coverage via our social media channels and providing summaries of key sessions. Stay tuned to follow our first-hand coverage.

#mmsm

Event Website

Map Data
Map data ©2019 Google
Map DataMap data ©2019 Google
Map data ©2019 Google

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology